Evaluation of Delestrogen and Parlodel as a luteolytic agent in humans.
Ten women ages 22 to 39 years were treated with a single injection of Delestrogen on day 19 of the menstrual cycle and increasing doses of Parlodel on days 19 to 23. This treatment resulted in a shortening of the luteal phase and a decrease in the production of progesterone and had no effect on serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), or prolactin levels. Side effects reported with this therapy included lethargy, dizziness, nausea, vomiting, hot flashes, depression, and nasal congestion. These preliminary clinical data suggest a combination of estrogen and bromocriptine regimen is luteolytic and may be useful as an interceptive abortifacient preparation in the human being.
D000328:Adult; D000818:Animals; D001971:Bromocriptine / Q000009:adverse effects / Q000494:pharmacology*; D003338:Corpus Luteum / Q000187:drug effects*; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D011374:Progesterone / Q000097:blood
D006065:Gonadotropins, Pituitary; D001971:Bromocriptine; D011374:Progesterone; D004958:Estradiol